Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tamsulosin in children with neuropathic bladder
NCT00796614Phase 3Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Jan 2008
- Primary completion
- Feb 2009
- Modality
- Small Molecules
- Countries
- 13
01
Overview
Phase 3, randomised, double-blind trial of tamsulosin in neurogenic bladder (4 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Response to Treatment Defined as Patients Who Decrease Their Detrusor Leak Point Pressure (LPP) to <40 cm H2O at 14 weeks. Started Jan 2008; status: completed.
02
Drugs
tamsulosin
03
Conditions
neurogenic bladder
Beyond the preview
Go deeper on NCT00796614.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00796614.